Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J.
Kaufman JL, et al. Among authors: casneuf t.
Blood Cancer J. 2020 Nov 3;10(11):111. doi: 10.1038/s41408-020-00375-2.
Blood Cancer J. 2020.
PMID: 33149130
Free PMC article.
Clinical Trial.